Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. (Nasdaq: ACCD) is a pioneering Personalized Healthcare company devoted to providing exceptional healthcare experiences to millions of people and their families, enabling them to live their healthiest lives. Accolade's range of solutions targets employers, health plans, and consumers by integrating virtual primary care, mental health services, expert medical opinions, and top-tier care navigation. Their innovative platform leverages cloud-based intelligent technology, coupled with expert clinical teams, including registered nurses, physician medical directors, pharmacists, and primary care physicians, to deliver comprehensive advocacy and healthcare services.
The company has been recognized for its significant contributions to the healthcare industry, such as being named one of Forbes' 25 most promising companies and achieving a spot on Inc. 500's list of America's fastest-growing private companies. Accolade's mission is to guide individuals through the complexities of the healthcare system, thereby enhancing outcomes and reducing costs for employers and health plans.
Accolade has recently gained considerable attention for its impressive 227% revenue growth, attributed to a relentless focus on delivering exceptional outcomes. This achievement earned Accolade a place in the Deloitte Technology Fast 500™ list for 2023. CEO Rajeev Singh credits the company's innovative approach and dedicated team for this remarkable performance.
Accolade's Trusted Partner Ecosystem, launched in 2019, exemplifies its commitment to comprehensive healthcare solutions. This ecosystem includes partnerships with leading companies like Kindbody and Noom, expanding access to specialized services such as fertility and metabolic health.
Accolade's financial health remains robust, with recent quarterly results showcasing a significant reduction in net loss and positive adjusted EBITDA, indicating a promising trajectory toward sustainable growth and profitability.
With a consumer satisfaction rating consistently over 90%, Accolade is steadily advancing its vision of transforming healthcare through predictive engagement, proactive care, and by addressing barriers to access and continuity of care. The company's forward-thinking approach ensures it remains at the forefront of healthcare innovation, making a significant impact on the industry and the lives of the people it serves.
For more information, visit accolade.com.
Accolade, Inc. (Nasdaq: ACCD) has announced the pricing of $250 million in 0.50% convertible senior notes due 2026. The private placement is aimed at qualified institutional buyers under Rule 144A of the Securities Act. The initial conversion rate is set at 19.8088 shares per $1,000 principal amount, equating to a conversion price of $50.48 per share, reflecting a 32.5% premium over the last stock price. Proceeds are expected to be approximately $242.4 million and will be utilized for corporate purposes including capital expenditures and acquisitions. The offering closes on March 29, 2021.
Accolade, Inc. (ACCD) reported preliminary financial results for the fiscal year 2021, projecting Q4 revenue between $56.9 million and $57.9 million, and annual revenue between $168.0 million and $169.0 million. The net loss for Q4 is expected to be between $(7.1) million and $(5.6) million, with an annual net loss of $(53.0) million to $(51.5) million. Adjusted EBITDA for Q4 is projected between $0.6 million and $2.1 million, while the annual adjusted EBITDA is expected between $(29.0) million and $(27.5) million. Full results are due on May 5, 2021.
Accolade, Inc. (Nasdaq: ACCD) announced plans to offer $250 million in convertible senior notes due 2026 in a private placement. The offering aims to provide funds for corporate purposes, including working capital and strategic investments. An additional $37.5 million may be purchased by initial buyers. The notes will be unsecured, with interest accruing semiannually. Capped call transactions are intended to mitigate potential dilution from conversions. The offering is subject to market conditions and has not been registered under the Securities Act.
Accolade, Inc. (Nasdaq: ACCD) has finalized its acquisition of Innovation Specialists, LLC (d/b/a 2nd.MD) for up to $460 million. This strategic move combines expertise in benefit navigation, health advocacy, and expert medical opinions, enhancing healthcare navigation for over 9 million lives across 400 customers. The transaction includes $230 million in cash and stock, with an additional $100 million contingent upon revenue milestones. This merger is expected to expand Accolade’s addressable market by $22 billion.
Accolade, Inc. (NASDAQ: ACCD) will participate in two upcoming investor conferences: the BTIG Virtual MedTech Conference on February 17, 2021, at 4:00 p.m. E.T. and the SVB Leerink Global Healthcare Conference on February 24, 2021, at 9:20 a.m. E.T. Audio webcasts and presentation materials will be available at ir.accolade.com. Accolade offers personalized health and benefits solutions, aiding users in navigating the healthcare system, achieving high consumer satisfaction ratings and lowering healthcare costs.
Accolade (Nasdaq: ACCD) has appointed Cindy R. Kent to its board of directors, effective immediately. Kent, the current executive vice president of Brookdale Senior Living and former head of 3M's Infection Prevention Division, brings extensive healthcare and business operations experience. CEO Rajeev Singh expressed that her leadership will provide valuable insights as Accolade grows. Kent's proven track record includes overseeing significant revenue operations in major healthcare sectors. Additionally, the company announced the departure of board members Michael Yang and Jim Madden.
Accolade has announced its acquisition of 2nd.MD, a leading Expert Medical Opinion company, for up to $460 million. The deal involves $230 million in cash, $130 million in stock, and up to $100 million contingent on revenue milestones. This acquisition aims to enhance Accolade's healthcare navigation services, targeting a market expansion worth $22 billion. The integration is expected to be accretive to revenue growth in fiscal 2022, with the potential for significant employer savings per consultation. The transaction is anticipated to close by February 2021.
Accolade, Inc. (NASDAQ: ACCD) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 2:50 p.m. E.T. This event will include an audio webcast and presentation materials available on their investor relations website. Accolade specializes in personalized, technology-enabled healthcare solutions that help individuals navigate the healthcare system effectively. The company aims to empower users with over 90% consumer satisfaction and a Net Promoter Score (NPS) of 60.
Accolade, Inc. (NASDAQ: ACCD) reported a fiscal third-quarter 2021 revenue of $38.4 million, reflecting a 30% increase from $29.7 million in the same quarter last year. This growth was attributed to new customer additions across various market segments. The company raised its revenue outlook for the fiscal year to $162 million to $165 million, indicating a projected growth of 22% to 25% over fiscal year 2020. Despite a net loss of $(16.6) million, down from $(18.3) million, Accolade's adjusted gross profit rose 32%.
FAQ
What is the current stock price of Accolade (ACCD)?
What is the market cap of Accolade (ACCD)?
What does Accolade, Inc. do?
How has Accolade performed financially recently?
What is the Trusted Partner Ecosystem?
Who are Accolade's key partners?
What recognition has Accolade received?
What is Accolade's mission?
How does Accolade contribute to healthcare cost reduction?
How does Accolade engage with its members?
What is Accolade's customer satisfaction rating?
Where can I find more information about Accolade?
